hbv
Showing 1 - 25 of 50
HBV pgRNA on Long-term Outcomes in Hepatitis B Patients Treated
Not yet recruiting
- HBV
- HCC
- nucleoside analogues or interferon
-
Hefei, Anhui, China
- +9 more
Jul 20, 2023
Hiv, Syphilis, HBV Trial (TRI-MOM intervention)
Not yet recruiting
- Hiv
- +2 more
- TRI-MOM intervention
- (no location specified)
Jul 10, 2023
Liver Failure, Acute on Chronic, Hepatic Encephalopathy, HBV Trial in Guangzhou (Rifaximin 200 mg, Standard Treatment without
Recruiting
- Liver Failure, Acute on Chronic
- +5 more
- Rifaximin 200 mg
- Standard Treatment without Rifaximin
-
Guangzhou, Guangdong, ChinaThe Third Affiliated Hospital of Sun Yat-sen University
Mar 26, 2023
Early Diagnosis of Hepatocellular Carcinoma (HCC)
Recruiting
- HCC
- +4 more
- Biomarker dosage
-
Castellana Grotte, Bari, ItalyRCCS "Saverio de Bellis"
Mar 23, 2023
Single-cell RNA Sequencing Resolves Regulatory Role of HBV on
Recruiting
- HBV
- Primary Liver Cancer
- HBV DNA Sequencing
-
Wuhan, Hubei, ChinaZhongnan Hospital of Wuhan University
Dec 22, 2022
Hepatitis B Reactivation, Hematopoietic Stem Cell Transplantation, Antiviral Drug Trial in Seoul (Entecavir)
Enrolling by invitation
- Hepatitis B Reactivation
- +3 more
-
Seoul, Korea, Republic ofJeong Won Jang
Dec 16, 2022
Hepatocellular Carcinoma, HBV Trial (Hepatect CP 50 I.E./ml infusion solution)
Not yet recruiting
- Hepatocellular Carcinoma
- HBV
- Hepatect CP 50 I.E./ml infusion solution
- (no location specified)
Nov 9, 2022
NSCLC Stage IV, HIV, HBV Trial in Verona (Nivolumab and Ipilimumab)
Not yet recruiting
- NSCLC Stage IV
- +4 more
- Nivolumab and Ipilimumab
-
Verona, Veneto/Verona, ItalyCentro Ricerche Cliniche
Oct 26, 2022
HBV Trial in Wuhan (hUCMSCs)
Recruiting
- HBV
- hUCMSCs
-
Wuhan, Hubei, ChinaZhongnan Hospital of Wuhan University
Jun 27, 2022
Access HBV Assays - European Union Clinical Trial Protocol -
Recruiting
- HBV
- Access HBV serological marker assays on the DxI 9000 Access Immunoassay Analyzer and CE-marked predicate assays
-
Amiens, France
- +4 more
Jun 23, 2022
Liver Fibrosis in Zambian HIV-HBV Co-infected Patients
Active, not recruiting
- Human Immunodeficiency Virus
- +6 more
- Anti-HIV Agents
-
Lusaka, ZambiaCentre for Infectious Disease Research in Zambia (CIDRZ)
Jun 1, 2022
Chronic Hepatitis B Virus Infection in Zambia
Active, not recruiting
- HBV
- +5 more
- Standard of care
-
Lusaka, ZambiaTropical Gastroenterology and Nutrition Group
Jun 1, 2022
HBV, Chronic HBV Infection Trial in Worldwide (TAF, TDF, TAF Placebo)
Active, not recruiting
- HBV
- Chronic HBV Infection
- TAF
- +3 more
-
Los Angeles, California
- +159 more
Mar 17, 2022
HBV, Chronic HBV Infections Trial in China (TAF, TDF, TAF Placebo)
HBV Trial in Taichung (Antroquinonol, )
Recruiting
- HBV
- Antroquinonol
- placebo
-
Taichung, TaiwanChung Shan Medical University Hospital
Mar 14, 2022
Hepatic Decompensation and Survival Outcomes in Pediatric
Recruiting
- Cirrhosis
- +6 more
- Prediction model
-
Chengdu, Sichuan, ChinaWest China Hospital, Sichuan University
Jan 5, 2022
HCV, HBV, Hiv Trial in Paris (HCV, HBV, HIV tests)
Terminated
- HCV
- +2 more
- HCV, HBV, HIV tests
-
Paris, FranceLariboisière
Nov 19, 2021
Among Inflammation, Physical and Mental Health in Chronic
Recruiting
- Chronic Infectious Disease
- +7 more
-
Napoli, ItalyDepartment of Psychiatry - University of Campania "Luigi Vanvite
Nov 6, 2021
HBV, POST LIVER TRANSPLANT Trial in Shanghai (Tenofovir Alafenamide 25 MG)
Active, not recruiting
- HBV
- POST LIVER TRANSPLANT
- Tenofovir Alafenamide 25 MG
-
Shanghai, Shanghai, ChinaZhongshan hospital, Fudan University
Sep 22, 2021
Cirrhosis, Liver, Vaccination Failure, HBV Trial (IMIQUIMOD cream, HEPATITIS B SURFACE ANTIGEN)
Not yet recruiting
- Cirrhosis, Liver
- +3 more
- IMIQUIMOD cream
- HEPATITIS B SURFACE ANTIGEN
- (no location specified)
Aug 27, 2021
Hepatitis B, Chronic Hep B, HBV Trial in Guangzhou, Shanghai, Chengdu (APG-1387, Entecavir 0.5 mg)
Recruiting
- Hepatitis B
- +2 more
- APG-1387
- Entecavir 0.5 mg
-
Guangzhou, Guangdong, China
- +3 more
Aug 25, 2021
HBV, Inflammatory Arthritis Trial (Tenofovir alafenamide)
Not yet recruiting
- HBV
- Inflammatory Arthritis
- Tenofovir alafenamide
- (no location specified)
Aug 5, 2021
Kidney Transplantation, HBV Trial in Chengdu (prophylaxis regimen)
Recruiting
- Kidney Transplantation
- HBV
- prophylaxis regimen
-
Chengdu, Sichuan, ChinaTao Lin
Jul 21, 2021
HBV Trial in Tainan
Recruiting
- HBV
-
Tainan, TaiwanNational Cheng-Kung University Hospital
May 11, 2021
HBV Trial in Paris (o receive treatment with anti-CD20 (rituximab or ocrelizumab) and to be vaccinated against hepatitis B)
Recruiting
- HBV
- o receive treatment with anti-CD20 (rituximab or ocrelizumab) and to be vaccinated against hepatitis B
-
Paris, Ile De France, FranceValérie POURCHER
Feb 2, 2021